Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women

Project Title Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women
Date Posted
Wednesday, December 20, 2017
Project ID
cder_mpl1r_wp057_nsdp_v01
Status
Complete
Deliverables
Description

This report contains estimates of use of five tumor necrosis factor (TNF)-alpha inhibitors, etanercept, adalimumab, infliximab, certolizumab, and golimumab, that occurred during a pregnancy resulting in a liveborn delivery, or within 90 days prior to the estimated start of pregnancy. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2004 to September 30, 2015. This request was distributed to 16 Data Partners on June 27, 2017.

Medical Product
adalimumab
certolizumab
etanercept
golimumab
infliximab
tumor necrosis factor (TNF) alpha inhibitor
Population / Cohort
Females 15-54 years of age
Time Period
January 1, 2004 - September 30, 2015
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER